Mid-stream Development Of A New Therapeutic Inhibitor For EBV-associated Malignancies

We aim to develop an Epstein-Barr virus (EBV) inhibitor for therapeutic intervention of EBV-associated malignancies. Basic CMC of the candidate drugs will be defined, formulation of drug delivery will be determined. The minimum (ED) and median (ED50) effective doses for tumor size reduction in response to our candidate drugs will be identified, one lead compound will be chosen. MoA, PK, TOX, and
biodistribution of the lead compound will be determined.